In contrast to T47D cells, BC-ER cells grew slower

after being treated with E2, and cell proportion in the G2 + S period was reduced. This result is consistent with previous studies showing that E2 inhibits the growth of ERα-positive breast cancer cells transformed from ERα-negative cells [29–31]. We supposed that drug resistance of BC-ER cells was due to its low growth velocity in the presence of E2. However, the apoptosis-regulating proteins Bcl-2 and Bax, which are considered as important proteins mediating drug resistance in ERα-positive breast cancer cells, may not play a role in the formation of drug resistance of BC-ER cells. The results obtained above showed that ERα activation increased the sensitivity of natural ERα-positive T47D breast cancer cells to different chemotherapeutic agents, and that the inhibition of www.selleckchem.com/products/gsk126.html ERα activation by fulvestrant resulted in chemoresistance. Meanwhile, ERα activation decreased learn more the chemosensitivity of ERα-stably transfected BC-ER cells. Compared with ERα-negative BC-V cells, ERα-positive BC-ER cells presented higher resistance to multiple chemotherapeutic agents. We could not explain these phenomena

by stating that ERα mediated the drug resistance of breast cancer cells to chemotherapy through the regulation of the expression of Bcl-2 and Bax. This is because ERα activation upregulated the expression of Bcl-2 in natural ERα-positive breast cancer cells, however, ERα activation downregulated Bcl-2 expression and upregulated Bax expression in ERα-positive cancer cells transformed Megestrol Acetate from ERα-negative breast cancer cells. We explained this phenomenon through the influence of ERα on the growth of breast cancer cells, that is, ERα activation enhanced the growth of natural ERα-positive breast cancer cells, and eventually increased sensitivity to chemotherapeutic agents. However, for Bcap37 cells transformed from ERα-negative breast cancer cells, ERα activation

inhibited the growth of cancer cells, and increased the resistance of cancer cells to chemotherapeutic agents. Conclusions ERα activation was unable to induce the drug resistance of natural ERα positive T47D breast cancer cells. Although it increased the drug resistance of Bcap37 cells transformed from ERα-negative breast cancer cells, this was, however, attributable only to the inhibitory effect of E2 on the growth of these ERα-transfected Bcap37 cells. The observation was not applicable to common ERα-positive breast cancer cells. Taking together our in vitro and previous clinical findings, we indicated that, although ERα was associated with chemoresistance of breast cancers, ERα itself did not mediate this resistance process. This finding might explain why the co-application of the estrogen antagonist tamoxifen and the chemotherapeutic agents did not have good therapeutic effects in breast cancer therapy.

Cytoscape plug-in MCODE [52] was used to decompose the sub-network and 5 clusters with the score greater than 3 were identified. Acknowledgments This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Ministry of Education, Science and Technology (2011–0009233) and by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2012R1A5A2051384).

References 1. Kornberg A, Rao NN, Ault-Riche D: Inorganic polyphosphate: A molecule of many functions. Annu Rev Biochem 1999, 68:89–125.PubMedCrossRef 2. Marcy JA, Kraft AA, Hotchkiss DK, Molins RA, Olson DG, Walker HW, Merkenich K: Effects of selected commercial phosphate products on the natural

bacterial flora of a cooked meat system. J Food Prot 1998, 53:391–393. 3. Molins RA, Kraft AA, selleck Walker HW, Rust RE, Olson DG, Merkenich K: Effect of inorganic polyphosphates R788 on ground beef characteristics: microbiological effects on frozen beef patties. J Food Sci 1987, 52:46–49.CrossRef 4. Jen CM, Shelef LA: Factors affecting sensitivity of Staphylococcus aureus 196E to polyphosphates. Appl Environ Microbiol 1986, 52:842–846. 5. Knabel SJ, Walker HW, Hartman PA: Inhibition of Aspergillus flavus and selected Gram-positive bacteria by chelation of essential metal cations by polyphosphate. J Food Prot 1991, 54:360–365. 6. Lee RM, Hartman PA, Olson DG, Williams FD: Bactericidal and bacteriolytic effects of selected food-grade phosphates, using

Staphylococcus aureus as a model system. J Cell press Food Prot 1994, 57:276–283. 7. Post FJ, Krishnamurty GB, Flanagan MD: Influence of sodium hexametaphosphate on selected bacteria. Appl Microbiol 1963, 11:430–435.PubMedCentralPubMed 8. Zaika LL, Kim AH: Effect of sodium polyphosphates on growth of Listeria monocytogenes . J Food Prot 1993, 56:577–580. 9. Rajkowski KT, Calderone SM, Jones E: Effect of polyphosphate and sodium chloride on the growth of Listeria monocytogenes and Staphylococcus aureus in ultra-high temperature milk. J Dairy Sci 1994, 77:1503–1508. 10. Maier SK, Scherer S, Loessner MJ: Long-chain polyphosphate causes cell lysis and inhibits Bacillus cereus septum formation, which is dependent on divalent cations. Appl Environ Microbiol 1999, 65:3942–3949. 11. Brown AT, Ruh R Jr: Negative interaction of orthophosphate with glycolytic metabolism by Streptococcus mutans as a possible mechanism for dental caries reduction. Arch Oral Biol 1977, 22:521–524. 12. Shibata H, Morioka T: Antibacterial action of condensed phosphates on the bacterium Streptococcus mutans and experimental caries in the hamster. Arch Oral Biol 1982, 27:809–816. 13.

J Bacteriol 1994, 176:7532–7542.PubMed 30. Yuste L, Rojo F: Role of the crc gene in catabolic repression of the Pseudomonas putida GPo1 alkane degradation pathway. J Bacteriol 2001, 183:6197–6206.PubMedCrossRef 31. Putrinš M, Tover A, Tegova R, Saks Ü, Kivisaar M: Study of factors which negatively affect expression of the phenol degardation operon

pheBA in Pseudomonas putida . Microbiology 2007, 153:1860–1871.PubMedCrossRef Wnt inhibitor 32. Morales G, Linares JF, Beloso A, Albar JP, Martínez JL, Rojo F: The Pseudomonas putida Crc global regulator controls the expression of genes from several chromosomal catabolic pathways for aromatic compounds. J Bacteriol 2004, 186:1337–1344.PubMedCrossRef 33. Moreno R, Rojo F: The target for the Pseudomonas putida Crc global regulator in the benzoate degradation pathway is the BenR transcriptional regulator. J Bacteriol buy Quizartinib 2008, 190:1539–1545.PubMedCrossRef 34. Moreno R, Fonseca P, Rojo F: The Crc global regulator inhibits the Pseudomonas putida pWW0 toluene/xylene assimilation pathway by repressing the translation of regulatory

and structural genes. J Biol Chem 2010, 285:24412–24419.PubMedCrossRef 35. Hester K, Madhusudhan K, Sokatch J: Catabolite repression control by Crc in 2xYT medium is mediated by posttranscriptional regulation of bkdR expression in Pseudomonas putida . J Bacteriol 2000, 182:1150–1153.PubMedCrossRef 36. O’Toole G, Gibbs K, Hager P, Phibbs P Jr, Kolter R: The global carbon metabolism regulator Crc is a

component of a singnal transduction pathway required for biofilm development by Pseudomonas aeruginosa . J Bacteriol 2000, 182:425–431.PubMedCrossRef 37. Kaur R, Macleod J, Foley W, Nayudu M: Gluconic acid: An antifungal agent produced by Pseudomonas species in biological control of take-all. Phytochemistry 2006, 67:595–604.PubMedCrossRef 38. de Werra P, Péchy-Tarr M, Keel C, Maurhofer Etomidate M: Role of gluconic acid production in the regulation of biocontrol traits of Pseudomonas fluorescens CHA0. Appl Environ Microbiol 2009, 75:4162–4174.PubMedCrossRef 39. Takeuchi K, Kiefer P, Reimmann C, Keel C, Rolli J, Vorholt JA, Haas D: Small RNA-dependent expression of secondary metabolism is controlled by Krebs cycle function in Pseudomonas fluorescens . J Biol Chem 2009, 284:34976–34985.PubMedCrossRef 40. Thomas-Chollier M, Sand O, Turatsinze JV, Janky R, Defrance M, Vervisch E, Broheé S, van Helden J: RSAT: regulatory sequence analysis tools. Nucleic Acids Res 2008, 36:W119-W127.PubMedCrossRef 41.

(A) HRTEM image showing a single QD of InAs buried in the GaAs buffer layer. (B) Fast flourier transformation (FFT) image of (A) providing

electron diffractions of both GaAs and InAs phases. (C) Indexing of the FFT image indicating a typical molecular beam epitaxy orientation (cubic parallel orientation) between InAs and GaAs viewed at the direction . (D) An inverse FFT (IFFT) image formed by (111) diffraction spots. (E) IFFT image of InAs QD exhibits planar mismatch and dislocations marked by T symbol. (F) IFFT image of GaAs wetting layer exhibits lattice deformation selleck kinase inhibitor and dislocations marked by T symbol. (G) HRTEM image of one small-sized QD without any dislocations. In order to access the effect of the Sb spray on the defect structure of the QDs, an InAs QD of similar size and shape from sample 2 was analyzed. Its high-resolution TEM image as shown in Figure 3A shows that the QD has a base width of about 13 nm and a height of about 4 nm. A relative uniform stress field appeared around the Sb-sprayed QD, and especially, there is almost no light and dark contrast caused by the strain field in the GaAs wetting layer, indicating

that less stress and dislocations were generated. These observed features are well in agreement with the IFFT analysis presented in Figure 3. Figure 3B shows the IFFT image of the QD showing undetectable lattice deformation at the interface of InAs and GaAs. An IFFT image formed PD-0332991 nmr by only including the (111) plane reflections revealed only two dislocations located at the interfacial region of the QD and GaAs (Figure 3C). A similar IFFT analysis was unable to detect any dislocation in the wetting layer. In other words, the addition of Sb appeared to passivate the defects in the vicinity of the QDs. This is unlike the other GABA Receptor InAs/GaAs QD systems where defects of dislocation loops and stack faults were even observed to have penetrated

the spacer layer and extended to the surface [21, 28]. Our HRTEM results show that the 30-s Sb spray process that we adopted in our fabrication can greatly reduce the structural defects and dislocations of our InAs/GaAs system and prevent the formation of extended defects. The reduction of defects is undoubtedly related to the Sb incorporation in the lattice and the formation of GaSb [29]. The formation and intermixing of GaAsSb with InAs would result in less stress since the lattice misfit between InAs and GaAsSb is smaller than that between GaAs and InAs. It is known that the key impediment to the application of QD-based devices is that a good proportion of the QDs may not be active because of the non-radiative recombination through defects and dislocations around the QD-cap interface [29]. Thus, the Sb spray is expected to improve the performance of QD-based devices through minimizing the defects and dislocations in the InAs/GaAs QD system and therefore to keep many quantum dots active [30].

Schmidt VA, Chiariello CS, Capilla E, Miller F, Bahou WF: Development of hepatocellular carcinoma in Iqgap2-deficient mice is IQGAP1 dependent. Mol Cell Biol 2008, 28:1489–1502.PubMedCrossRef 61. Hoshida Y, Nijman SM, Kobayashi M, et al.: Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009, 69:7385–7392.PubMedCrossRef 62. Zhu Y, Sun Z, Han Q, et al.: Human mesenchymal stem cells inhibit cancer cell proliferation by secreting Copanlisib ic50 DKK-1. Leukemia 2009,23(5):925–33.PubMedCrossRef 63. Wei W, Chua M, Grepper S, So SK: Blockade

of Wnt-1 signaling leads to anti-tumor effects in hepatocellular carcinoma cells. Mol Cancer 2009, 8:76.PubMedCrossRef 64. Djouad F, Bony C, Apparailly F, et al.: Earlier onset of syngeneic tumors in the presence of mesenchymal stem cells. Transplantation 2006, 82:1060.PubMedCrossRef 65. Etheridge SL, Spencer GJ, Heath DJ, et al.: Expression profiling and functional analysis of wnt signaling mechanisms in mesenchymal stem cells. Stem Cells 2004, 22:849.PubMedCrossRef 66. Ishikawa H, Nakao K, Matsumoto K, et al.: Bone marrow engraftment in a rodent model of chemical

carcinogenesis but no role in the histogenesis of hepatocellular carcinoma. Gut 2004, 53:884–889.PubMedCrossRef 67. Guest I, Ilic Z, Ma J, et al.: Direct and indirect contribution of bone marrow derived cells to cancer. Int J Cancer 2010,126(10):2308–18.PubMed 68. Spaeth EL, Dembinski JL, Sasser AK, et al.: Mesenchymal stem check details cell transition to tumor-associated fibroblasts contributes to fibrovascular network expansion and tumor progression. PLoS One 2009, 4:e4992.PubMedCrossRef 69. Chen L, Tredget EE, Wu PYG, Wu Y: Paracrine factors of mesenchymal 17-DMAG (Alvespimycin) HCl stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PloS One 2008, 3:e1886.PubMedCrossRef 70. Amé-Thomas P, Maby-El Hajjami H, Monvoisin C, et al.: Human mesenchymal stem cells isolated from bone marrow and lymphoid organs support tumor B-cell growth: role of stromal cells in follicular lymphoma pathogenesis. Blood

2007, 109:693–702.PubMedCrossRef 71. Secchiero P, Zorzet S, Tripodo C, Corallini F, et al.: Human bone marrow mesenchymal stem cells display anti-cancer activity in SCID mice bearing disseminated non-Hodgkin’s lymphoma xenografts. PLoS One 2010,5(6):e11140.PubMedCrossRef 72. Khakoo AY, Pati S, Anderson SA, et al.: Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi’s sarcoma. J Exp Med 2006, 203:1235–1247.PubMedCrossRef 73. Otsu K, Das S, Houser SD, et al.: Concentration-dependent inhibition of angiogenesis by mesenchymal stem cells. Blood 2009, 113:4197–4205.PubMedCrossRef 74. Thorgeirsson SS, Grisham JW: Hematopoietic cells as hepatocyte stem cells: a critical review of the evidence. Hepatology 2006, 43:2–8.PubMedCrossRef 75. Sancho-Bru P, Najimi M, Caruso M, et al.

J Bacteriol 2001, 183:3117–3126.PubMedCrossRef 10. Joyce SA, Brachmann AO, Glazer I, Lango L, Schwar G, Clarke EPZ-6438 clinical trial DJ, Bode HB: Bacterial biosynthesis of a multipotent stilbene. Angewantde Chemie 2008, 47:1942–1945.CrossRef 11. Watson

RJ, Joyce SA, Spencer GV, Clarke DJ: The exbD gene of Photorhabdus temperata is required for full virulence in insects and symbiosis with the nematode Heterorhabditis . Mol Microbiol 2005, 56:763–773.PubMedCrossRef 12. Braun V: Energy-coupled transport and signal transduction through the gram-negative outer membrane via TonB-ExbB-ExbD-dependent receptor proteins. FEMS Microbiol Rev 1995, 16:295–307.PubMedCrossRef 13. Braun V, Braun M: Active transport of iron and siderophore antibiotics. Curr Opin Microbiol 2002, 5:194–201.PubMedCrossRef 14. Andrews SC, Robinson AK, Rodriguez-Quinones F: Bacterial iron homeostasis. FEMS Microbiol Rev 2003, 27:215–237.PubMedCrossRef 15. Wandersman C, Delepelaire P: Bacterial iron sources: from siderophores to hemophores. Annu Rev Microbiol 2004, 58:611–647.PubMedCrossRef 16. Faraldo-Gomez JD, Sansom MS: Acquisition of siderophores in gram-negative bacteria.

Nat Rev Mol Cell Biol 2003, 4:105–116.PubMedCrossRef 17. Andrews SC: Iron storage in bacteria. Adv Microb Physiol 1998, 40:281–351.PubMedCrossRef 18. Papp-Wallace KM, Maguire ME: Manganese transport and the role of manganese in virulence. Annu Rev Microbiol 2006, 60:187–209.PubMedCrossRef 19. Duchaud E, Rusniok C, Frangeul L, Buchrieser C, Givaudan A, Taourit S, Bocs S, Boursaux-Eude C, Chandler M, Charles JF, et al.: The genome sequence of the entomopathogenic bacterium Photorhabdus luminescens . Nat Biotechnol 2003, 21:1307–1313.PubMedCrossRef BMN 673 solubility dmso 20. Ciche TA, Blackburn M, Carney JR, Ensign JC: Photobactin: a catechol siderophore produced by Photorhabdus luminescens , an entomopathogen

mutually associated with Heterorhabditis bacteriophora NC1 nematodes. Appl Environ Microbiol 2003, 69:4706–4713.PubMedCrossRef 21. Cartron ML, Maddocks S, Gillingham P, Craven CJ, Andrews SC: Feo–transport of ferrous iron into bacteria. Biometals 2006, 19:143–157.PubMedCrossRef 22. Kehres DG, Maguire ME: Emerging themes in manganese transport, biochemistry and pathogenesis in bacteria. FEMS Microbiol Rev 2003, 27:263–290.PubMedCrossRef 23. Janakiraman A, Slauch JM: The putative iron transport system SitABCD Protein kinase N1 encoded on SPI1 is required for full virulence of Salmonella typhimurium . Mol Microbiol 2000, 35:1146–1155.PubMedCrossRef 24. Kehres DG, Janakiraman A, Slauch JM, Maguire ME: SitABCD is the alkaline Mn(2+) transporter of Salmonella enterica serovar Typhimurium. J Bacteriol 2002, 184:3159–3166.PubMedCrossRef 25. Anjem A, Varghese S, Imlay JA: Manganese import is a key element of the OxyR response to hydrogen peroxide in Escherichia coli . Mol Microbiol 2009, 72:844–858.PubMedCrossRef 26. Xu J, Hurlbert RE: Toxicity of irradiated media for Xenorhabdus spp. Appl Environ Microbiol 1990, 56:815–818.PubMed 27.

As a result, high influxes of such phagocytes are expected at the infection site upon pathogen invasion. For instance, a high influx of neutrophils was detected at the infection site of S. aureus bone infection [24]. Unfortunately, some pathogens can survive within these phagocytes after being phagocytized which may lead to chronic diseases [25,26]. It was reported that S. aureus can survive within neutrophils and its survival may have contributed to infection persistence as well as dissemination in vivo [7]. Neutrophils are short-lived and are unlikely to carry intracellular pathogens for long [27]. Macrophages, however, are long-lived and may

possibly allow surviving pathogens to invade the circulatory system from Ibrutinib concentration localized infection sites [28]

and thereby may be more likely to contribute to chronic and recurrent infections. The aims of this study were to compare S. aureus internalization in a phagocytic cell (i.e. macrophage) to a non-phagocytic cell (i.e. osteoblast) and to investigate macrophage and osteoblast responses upon S. aureus infection. We hypothesized that S. aureus can internalize into macrophages and osteoblasts and lead to differential responses. Results Characterization of S. aureus infection of osteoblasts and macrophages S. aureus was incubated with osteoblasts or macrophages for 2 h, with a multiplicity of infection (MOI) from 100:1 to 1000:1; the MOI represents the S. aureus to osteoblast or macrophage ratio. Osteoblasts and macrophages were both found to be infected. However, significantly higher (~100 fold) numbers of NVP-BKM120 mw intracellular S. aureus were found within macrophages compared to osteoblasts (Figure 1A); the intracellular colony forming units (CFUs) for infected macrophages and osteoblasts were approximately

3.5 × 106 and 3.1 × 104 CFU/(105 cells), respectively. No significant differences Org 27569 were observed in the same cell type at the various MOIs studied (i.e. 100:1, 500:1, and 1000:1). By contrast, significantly lower viability was observed in macrophages compared to osteoblasts at 2 h infection; the viability of macrophages and osteoblasts were 62-78% and 90-95%, respectively (Figure 1B). No significant differences in viability for the same cell type at the MOIs investigated (i.e. 100:1, 500:1, and 1000:1) were noted following the 2 h infection. Figure 1 S. aureus infection of osteoblasts and macrophages. (A) Live intracellular S. aureus and (B) viability of osteoblasts and macrophages at different MOIs (100:1, 500:1, and 1000:1) for 2 h. * p < 0.05 and ** p < 0.001 compared to osteoblasts at the same MOI. (C) Live intracellular S. aureus and (D) viability of osteoblasts and macrophages at an MOI of 500:1 for various infection times. ** p < 0.001 compared to osteoblasts at the same infection time, & p < 0.01 compared to macrophages at infection times 0 and 0.5 h, ^ p < 0.

Disorders in the mixed crystal TiO2 affect the optical properties of TiO2[17, 18]. The existence of the ARJs could enhance the disorders in the TiO2 films, which will change the samples’ physical properties. Our recent work indicates that both doping and phase composition affect

the optical properties of TiO2 films [19]. The ARJs could affect not only the optical but also the magnetic properties of the TiO2 films [20]. However, to the best of our knowledge, the effects of phase composition on the magnetic properties of doped TiO2 films have seldom been reported. Recently, Bahadur et al. found that the magnetic Alectinib moment of the Ni-doped mixed crystalline TiO2 powders increases and then decreases with increasing Ni content due to the change

of spin ordering [21]. However, the influence of phase composition on the magnetic properties has not been taken into account in their studies. In this paper, transition metal (TM)-doped TiO2 films (TM = Co, Ni, and Fe) were deposited on Si(100) substrates by a sol–gel method. The influence of Co, learn more Ni, and Fe doping on the crystalline structure of the TiO2 films was compared. The magnetic and optical properties of the TM-doped TiO2 films were investigated. The correlation between phase composition and magnetic and optical properties was studied, and the possible mechanism was discussed. These results will be useful for understanding the magnetic origin of oxide DMS. Methods Synthesis of TM-doped TiO2 films, Ti1 − x TM x O2 (TM = Co, Ni, and Fe; x = 0, 0.01, and 0.03), was achieved on Si(100) substrates by sol–gel method. The precursor solutions of the TM-doped TiO2

films were obtained from tetrabutyl titanate, cobaltous acetate, nickel acetate, and ferric nitrate with ethanol and acetylacetone as the solvent and the chemical modifier, respectively. The details of the preparation procedure are reported elsewhere [22]. For example, to prepare a Ni-doped TiO2 solution, analytically pure nickel acetate (Ni[CH3COO]2) and titanium butoxide (Ti[O(CH2)3CH3]4) Bay 11-7085 were used as the starting materials. Ni doping was achieved by dissolving nickel acetate in a solution with an appropriate volume ratio of ethanol (CH3CH2OH)/acetic acid (CH3COOH) at 60°C. Titanium butoxide and an equal amount of acetylacetone (CH3COCH2COCH3) were dissolved in ethanol at 30°C. Then the two solutions were mixed slowly together at room temperature. In order to get a homogenous precursor, the mixture was stirred drastically in the magnetic stirrer for 2 h at 50°C. Finally, the 0.3 mol/L precursor solution was acquired and became transparent without precipitation even after 4 months. The silicon substrates were cleaned in an ultrasonic bath for 20 min using acetone (CH3COCH3), ethanol, and deionized water, respectively.

In fact, a significant increase in exercise intensity was reported for the final 15 min (an all out portion of the exercise bout) for the caffeine + carbohydrate and electrolyte beverage, but not for the carbohydrate + electrolyte drink, or placebo. In conclusion, no significant differences in blood volume were present for any of the three treatments; therefore, caffeine did not adversely affect hydration and thus performance of long duration FDA approved Drug Library cost in highly trained

endurance athletes [92]. Finally, Del Coso and colleagues [93] examined the effects of a moderate dose of caffeine in combination with sustained cycling at 60% VO2max. Seven endurance-trained males consumed each of the following conditions during 120 min of exercise: no rehydration, water, carbohydrate-electrolytes solution, and each of these three treatments with the addition of caffeine at 6 mg/kg

in capsule form. Results were conclusive, and indicated caffeine alone at 6 mg/kg did not significantly affect sweat rate during exercise, nor did ingestion of caffeine in combination with water or a carbohydrate-electrolytes solution. In addition, heat dissipation was not negatively affected [93]. Sirolimus Therefore, while there may be an argument for caffeine-induced dieresis at rest, the literature does not indicate any significant negative effect of caffeine on sweat loss and thus fluid balance during exercise that would adversely affect performance. Caffeine and Doping It has been shown that caffeine supplementation in the range of 3-6 mg/kg can significantly enhance both endurance and high-intensity performance in trained athletes. Consequently, the International Olympic MYO10 Committee mandates an allowable limit of 12 μg of caffeine per ml of urine [6, 15]. A caffeine dose in the range of 9 – 13 mg/kg approximately one hour prior to performance will reach the maximum allowable urinary concentration for competition

[6]. Caffeine consumption and urinary concentration is dependent on factors such as gender and body weight [94]. Therefore, consuming 6-8 cups of brewed coffee that contain approximately 100 mg per cup would result in the maximum allowable urinary concentration [15, 94]. According to The National Collegiate Athletic Association, urinary concentrations after competition that exceed 15 μg/ml are considered to be illegal [95]. In addition, the World Anti-Doping Agency does not deem caffeine to be a banned substance [96], but has instead included it as part of the monitoring program [97] which serves to establish patterns of misuse in athletic competition. Conclusion The scientific literature associated with caffeine supplementation is extensive. It is evident that caffeine is indeed ergogenic to sport performance but is specific to condition of the athlete as well as intensity, duration, and mode of exercise.

Behav Brain Res 2001, 125: 279–284.PubMedCrossRef 16. Hooper SD, Bork P: Medusa: a simple tool for interaction graph analysis. Bioinformatics 2005, 21: 4432–4433.PubMedCrossRef 17. Haynes C, Oldfield CJ, Ji F, Klitgord N, Cusick ME, Radivojac

P, Uversky VN, Vidal M, Iakoucheva LM: Intrinsic disorder is a common feature of hub proteins from four eukaryotic interactomes. PLoS Comput Biol 2006, 2: e100.PubMedCrossRef 18. Ward JJ, McGuffin LJ, Bryson K, Buxton BF, Jones DT: The DISOPRED server for the prediction of protein disorder. Bioinformatics 2004, Dorsomorphin 20: 2138–2139.PubMedCrossRef 19. Gandhi TK, Zhong J, Mathivanan S, Karthick L, Chandrika KN, Mohan SS, Sharma S, Pinkert S, Nagaraju S, Periaswamy B, et al.: Analysis of the human protein interactome and comparison with yeast, worm

and fly interaction datasets. Nat Genet 2006, 38: 285–293.PubMedCrossRef 20. Fabregat I, Roncero C, Fernandez M: Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 2007, 27: 155–162.PubMedCrossRef 21. Fabregat I: Dysregulation of apoptosis in hepatocellular carcinoma cells. World J Gastroenterol 2009, 15: 513–520.PubMedCrossRef 22. Semczuk A, Jakowicki JA: Alterations of pRb1-cyclin D1-cdk4/6-p16(INK4A) pathway in endometrial carcinogenesis. Cancer Lett 2004, 203: 1–12.PubMedCrossRef 23. Lin L, Amin R, Gallicano GI, Glasgow E, Jogunoori W, Jessup JM, Zasloff M, Marshall JL, Shetty K, Johnson L, et al.: The MEK inhibitor STAT3 inhibitor NSC 74859 is Farnesyltransferase effective in hepatocellular cancers with disrupted TGF-beta signaling. Oncogene 2009, 28: 961–972.PubMedCrossRef 24. Matsuzaki K: Modulation of TGF-beta signaling during progression of chronic liver diseases. Front Biosci 2009, 14: 2923–2934.PubMedCrossRef 25. Hussain SP, Schwank J, Staib F, Wang XW, Harris CC: TP53 mutations and hepatocellular carcinoma: insights into the etiology and pathogenesis of liver cancer. Oncogene 2007, 26: 2166–2176.PubMedCrossRef 26. de Chassey B, Navratil V, Tafforeau L, Hiet MS, Aublin-Gex A, Agaugue S, Meiffren G, Pradezynski

F, Faria BF, Chantier T, et al.: Hepatitis C virus infection protein network. Mol Syst Biol 2008, 4: 230.PubMed 27. Kim S, Takahashi H, Lin WW, Descargues P, Grivennikov S, Kim Y, Luo JL, Karin M: Carcinoma-produced factors activate myeloid cells through TLR2 to stimulate metastasis. Nature 2009, 457: 102–106.PubMedCrossRef 28. Xu N, Yao HP, Sun Z, Chen Z: Toll-like receptor 7 and 9 expression in peripheral blood mononuclear cells from patients with chronic hepatitis B and related hepatocellular carcinoma. Acta Pharmacol Sin 2008, 29: 239–244.PubMedCrossRef 29. Paone A, Starace D, Galli R, Padula F, De Cesaris P, Filippini A, Ziparo E, Riccioli A: Toll-like receptor 3 triggers apoptosis of human prostate cancer cells through a PKC-alpha-dependent mechanism. Carcinogenesis 2008, 29: 1334–1342.PubMedCrossRef 30.